Drug lookup | Fillwise

FLUPHENAZINE HCL

3 general benefit · 3 not a benefit

Other products in the same Health Canada class (N05A, N05AB) — coverage varies; not interchangeable

Perphenazine (Trilafon): general benefit, Not a benefit
Prochlorperazine (Prochlorazine): general benefit, Not a benefit
Trifluoperazine (Trifluoperazine): general benefit, Not a benefit
Aripiprazole (Abilify Asimtufii): general benefit
Asenapine (Saphris): general benefit
Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Fluphenazine · DIN 00405345 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Fluphenazine · DIN 00405345 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-07-10 · brand FLUPHENAZINE · ATC N05AB02 FLUPHENAZINE · form Tablet · route Oral · ingredients FLUPHENAZINE HYDROCHLORIDE 1 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Fluphenazine: Formulary list price $0.1739/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1739 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2858 · Verify on the e-Formulary ↗ (DIN 00405345)

Source record

DIN 00405345: Fluphenazine Raw flags: sec3=Y Item: 281608030; group id 491; item number 1255; lccId None; manufacturer id AAP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.1739; ministry $0.1739 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00405345 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2858

Interchangeable products

Moditen HCL · DIN 00029378 · not recorded

Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405345

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fluphenazine · DIN 00410632 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Fluphenazine · DIN 00410632 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-07-10 · brand FLUPHENAZINE · ATC N05AB02 FLUPHENAZINE · form Tablet · route Oral · ingredients FLUPHENAZINE HYDROCHLORIDE 2 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Fluphenazine: Formulary list price $0.2252/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2252 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00410632: Fluphenazine Raw flags: sec3=Y Item: 281608029; group id 491; item number 1256; lccId None; manufacturer id AAP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.2252; ministry $0.2252 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00410632 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2861

Interchangeable products

Moditen HCL · DIN 00029386 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00410632

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fluphenazine · DIN 00405361 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Fluphenazine · DIN 00405361 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2014-03-12 · brand FLUPHENAZINE · ATC N05AB02 FLUPHENAZINE · form Tablet · route Oral · ingredients FLUPHENAZINE HYDROCHLORIDE 5 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Fluphenazine: Formulary list price $0.1720/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1720 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00405361: Fluphenazine Raw flags: sec3=Y Item: 281608028; group id 491; item number 1257; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1720; ministry $0.1720 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00405361 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2860

Interchangeable products

Moditen HCL · DIN 00029408 · not recorded

Shortage status: resolved shortage (ended 2024-09-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405361

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moditen HCL · PIN 00029378 · 1mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Check Health Canada brand DIN

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moditen HCL · DIN 00029378 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2006-06-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Check this DIN again

Moditen HCL: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00029378)

Source record

DIN 00029378: Moditen HCL Raw flags: notABenefit=Y, sec3=Y Item: 281608030; group id 491; item number 1255; lccId None; manufacturer id BQU Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00029378 Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Interchangeable products

Fluphenazine · DIN 00405345 · $0.1739

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moditen HCL · PIN 00029386 · 2mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand DIN

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moditen HCL · DIN 00029386 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2006-06-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Check this DIN again

Moditen HCL: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00029386)

Source record

DIN 00029386: Moditen HCL Raw flags: notABenefit=Y, sec3=Y Item: 281608029; group id 491; item number 1256; lccId None; manufacturer id BQU Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00029386 Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Interchangeable products

Fluphenazine · DIN 00410632 · $0.2252

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moditen HCL · PIN 00029408 · 5mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand DIN

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moditen HCL · DIN 00029408 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Check this DIN again

Moditen HCL: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00029408)

Source record

DIN 00029408: Moditen HCL Raw flags: notABenefit=Y, sec3=Y Item: 281608028; group id 491; item number 1257; lccId None; manufacturer id BQU Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00029408 Health Canada record for this brand: DIN 00582514 (Cancelled post market, 2003-07-28) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6076

Interchangeable products

Fluphenazine · DIN 00405361 · $0.1720

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

PERPHENAZINE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 2mg, 4mg, 8mg, 16mg · Tab

PROCHLORPERAZINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Tab

TRIFLUOPERAZINE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 1mg, 2mg, 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: manifestations of psychotic disorders

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PERPHENAZINE · Listed, not a benefit (4), General benefit (4) Indications PERPHENAZINE (perphenazine tablets) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00084763.PDF; date May 15, 2026; DIN 00335096; fetched 2026-09-10 Product monograph PROCHLORPERAZINE · General benefit (2), Listed, not a benefit (2) Indications PROCHLORAZINE (Prochlorperazine Maleate Tablets) is indicated for: • the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. PM: https://pdf.hres.ca/dpd_pm/00082835.PDF; date 2025-12-15; DIN 00886432; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS FLUPHENAZINE (fluphenazine hydrochloride) is indicated for: • Management of manifestations of psychotic disorders. • Treatment of behavioral disorders in adults. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLUPHENAZINE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics and 8 ADVERSE REACTIONS. 1.2 Geriatrics Geriatrics (>60 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX; 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00069653.PDF PM date: DEC 31, 1977 Source product: FLUPHENAZINE; DIN 00405345; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Moditen HCL: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026